ADCs, which merge antibodies with toxic drugs, enhance cancer treatment precision. Ongoing advancements improve their effectiveness, safety, and stability.
Life sciences face evolving and new regulations with the rise of CAGT and radiopharmaceuticals, requiring innovation and compliance to advance patient care.
New IAEA database will facilitate international access, monitor trends, and foster collaboration in the production and distribution of radiopharmaceuticals.
Eli Lilly invests $20M in Ionetix to secure actinium-225, crucial for radiopharma cancer therapies, addressing isotope shortages hindering industry growth.
Daiichi Sankyo and MSD strengthen their collaboration to globally develop and market three DXd-based ADCs, including MK-6070 for treating neuroendocrine tumors.
